UPDATE in Amgen v. Sandoz: Responses to Petitions for Rehearing en banc

Amgen v. Sandoz (filgrastim)  •  Approved Biosimilar Products  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions

Amgen and Sandoz have filed responses to each other’s petitions for rehearing en banc in Amgen v. Sandoz. Amgen’s response to Sandoz’s petition is available here, and Sandoz’s response to Amgen’s petition is available here.

We will be posting a summary of these responses later today, and will continue to monitor developments in this case here on the Big Molecule Watch.

Download PDF

Tagged with 

Comments are closed.